Fox Chase Cancer Center News

Falls No Longer Come Every Year at Fox Chase – Huntingdon Pike

PHILADELPHIA (December 21, 2023) —On November 8, 2023, the entire team at Fox Chase Cancer Center’s Huntingdon Pike ambulatory care clinic celebrated 365 days of successfully preventing patient falls. While falls were never common at HP, the nursing staff developed a home-grown recipe for fall prevention that included both new procedures and an overall dedication to finding and eliminating potential hazards. As a result, they have gone fall-free for an entire year.
VIEW STORY

Fox Chase Radiation Oncologist Dr. Rebecca Shulman Receives ASTRO-BCRF Emerging Investigator Award to Build a Diverse Scientific Workforce

PHILADELPHIA (December 20, 2023) — Rebecca Shulman, MD, an Assistant Professor in the Department of Radiation Oncology at Fox Chase Cancer Center, was recently recognized with the American Society for Radiation Oncology (ASTRO)-Breast Cancer Research Foundation (BCRF) Emerging Investigator Award to Build a Diverse Scientific Workforce.
VIEW STORY

Fox Chase Cancer Center’s Zoe Landau Wins Best Professional Poster Award From International Cancer Education Conference

PHILADELPHIA (December 14, 2023) — Zoe Landau, MPH, Project Manager in the lab of Linda Fleisher, PhD, MPH, a Research Professor in the Cancer Prevention and Control Research Program at Fox Chase Cancer Center, was recently recognized with the Best Professional Poster Award at the 2023 International Cancer Education Conference (ICEC) for her work detailing the mychoice digital health tool.
VIEW STORY

Fox Chase Cancer Center Physician Demonstrates Safety and Effectiveness of Myeloma Drug for Black or African American Patients at American Society of Hematology Meeting

PHILADELPHIA (December 11, 2023) — Asya Varshavsky-Yanovsky, MD, PhD, an Assistant Professor in the Department of Bone Marrow Transplant and Cellular Therapies at Fox Chase Cancer Center, has presented an analysis showing that the multiple myeloma drug elranatamab is safe and effective for Black or African American patients with relapsed/refractory multiple myeloma (RRMM).
VIEW STORY